William A LaFramboise

We perform molecular diagnostic testing across AHN using an innovative DNA-RNA NGS panel interrogating >500 cancer-relevant genes & transcripts. We perform basic & translational research to identify underlying mechanisms of tumorigenesis to direct the next generation of patient-specific and tumor-specific therapies and monitor their efficacy. Our technologies are optimized for challenging specimens (e.g. FFPE, cfDNA, CTC, exosomes) from single cell analysis to ddPCR to whole genome sequencing.